BMI View: Cambodia is increasingly looking to provide greater health coverage for its population and this
bodes well for pharmaceutical firms over the longer term. However, consistently low levels of government
health expenditure mean that there has been, and will c ..."
BMI View: Despite Cambodia's latest move to expand health coverage for workers, we highlight that the
country's lack of investments in healthcare means that the effective coverage of the policy will be low.
Consequently, any market potential within Cambodia will still ..."
BMI View: While the underdeveloped nature of its pharmaceutical and health care sector will bring about
commercial benefits for foreign investors, competition from relatively low risk and higher rewards markets
such as Vietnam means that Cambodia will remain low on in ..."
BMI View: Commercial opportunities for drugmakers in Cambodia will remain limited despite the rising
burden of both communicable and non-communicable diseases. Critically, the country's healthcare system
remains underdeveloped, hindering access to pharmaceuticals and ..."
BMI View: Despite improvements to the healthcare sector, high out of pocket expenditure means that
access to healthcare will remain a challenging issue in Cambodia. Further investments in the sector will
boost overall care quality and boost investments into the pharma ..."
BMI View: Despite Cambodia's aim towards universal health coverage, we highlight that financial
sustainability will remain a key issue. Nevertheless we highlight that pharmaceutical firms will benefit from
Headline Expenditure Projections
? Pharmaceu ..."
BMI View: Access to healthcare and financial sustainability are two key challenges that will weigh on the
effectiveness of Cambodia's universal healthcare programme. Expected to be implemented by 2025, the
scheme will provide revenue earning opportunities to pharmaceutical firm ..."
BMI View: The current lack of investment in healthcare in Cambodia will continue to deter foreign
pharmaceutical firms from entering the country. Consequently, we highlight that Cambodia will remain one
of the least attractive markets in South East Asia.
BMI View: Cambodia continues to lag behind its regional peers in terms of investment in healthcare
services. As a result, we maintain that multinational pharmaceutical firms will choose to invest in other
countries, such as Thailand and Vietnam.
Headline Expendi ..."
BMI View: Cambodia will continue to underperform other pharmaceutical markets in the Asia Pacific
region, given its low health and pharmaceutical expenditure as well as the rampant corruption in the
country. We highlight that, given such a profile, the country will pr ..."